CP
ABBV icon

Clarendon Private’s AbbVie ABBV Stock Holding History

Clarendon Private’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
4,478
-785
-15% -$169K 0.72% 36
2026
Q1 		$1.14M Buy
5,263
+124
+2% +$27.5K 0.88% 26
2025
Q4 		$1.17M Buy
5,139
+96
+2% +$21.9K 1% 23
2025
Q3 		$1.17M Buy
5,043
+446
+10% +$90.8K 1.06% 21
2025
Q2 		$853K Buy
4,597
+93
+2% +$17.3K 0.82% 34
2025
Q1 		$944K Buy
4,504
+565
+14% +$110K 1% 26
2024
Q4 		$700K Buy
+3,939
New +$724K 0.73% 37

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clarendon Private's ABBV Position: Q2 2026 in Review

Clarendon Private reduced its AbbVie (ABBV) stake by 15% in Q2 2026, selling an estimated $169K and leaving 4,478 shares worth $1.13M. The position accounts for 0.72% of the portfolio, ranked #36.

Clarendon Private first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.17M in Q4 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Clarendon Private held 4,478 shares of AbbVie worth $1.13M as of Q2 2026.
  • Clarendon Private sold 785 AbbVie shares in Q2 2026, an estimated $169K.
  • AbbVie made up 0.72% of Clarendon Private's portfolio in Q2 2026, its #36 holding.
  • Clarendon Private first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Clarendon Private's AbbVie position peaked at $1.17M in Q4 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clarendon Private's 13F filing for Q2 2026, filed 22 Jul 2026.